Home » Stocks » CDXC

ChromaDex Corporation (CDXC)

Stock Price: $9.42 USD -0.99 (-9.51%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $9.38 -0.04 (-0.43%) Jul 23, 7:54 PM
Market Cap 639.92M
Revenue (ttm) 59.60M
Net Income (ttm) -21.40M
Shares Out 64.16M
EPS (ttm) -0.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $9.42
Previous Close $10.41
Change ($) -0.99
Change (%) -9.51%
Day's Open 10.30
Day's Range 9.33 - 10.39
Day's Volume 725,800
52-Week Range 3.82 - 23.66

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., August 3, 2021 at 4:30 p.m. ET to discuss its financial results fo...

5 days ago - Business Wire

ChromaDex Corp. (NASDAQ: CDXC) participated in a virtual presentation at the Benzinga Small Cap Conference in May 2021. ChromaDex CEO Rob Fried also presented on a panel discussing "Investing in Longevi...

1 month ago - Benzinga

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) today announced the results of four recently published preclinical studies, highlighting new findings for its patented...

1 month ago - Business Wire

The company's flagship product was launched in Walmart stores across the U.S.

1 month ago - The Motley Fool

ChromaDex Corp (NASDAQ: CDXC) has launched its flagship consumer product Tru Niagen in Walmart Inc (NYSE: WMT), available in 3,800 stores across the U.S. The NAD+ booster will be offered to Walmart cust...

Other stocks mentioned: WMT
1 month ago - Benzinga

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) announced today the launch of its flagship consumer product Tru Niagen® in Walmart, available in 3,800 stores across t...

1 month ago - Business Wire

ChromaDex (CDXC) delivered earnings and revenue surprises of -33.33% and -10.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) today reported first quarter 2021 financial results. First Quarter 2021 and Recent Highlights Total net sales of $14.7 mil...

2 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #collaboration--ChromaDex Corp. (NASDAQ:CDXC) announced today that it entered into a strategic supply agreement for Niagen® with Ro, a healthcare-technology compan...

2 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 6, 2021 at 4:30 p.m. ET to discuss its financial results for ...

2 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) announced today it entered into a strategic supply agreement with Health & Happiness (H&H) Group, a global leader in p...

2 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #management--ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Fadi Karam as Chief Marketing Officer. Karam has spent his career driving consumer...

3 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #collaboration--ChromaDex Corp. (NASDAQ: CDXC) today announced a new research initiative with the Citrin Foundation of Singapore to study the effects of Niagen® ni...

3 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenti...

4 months ago - Business Wire

Investors need to pay close attention to ChromaDex (CDXC) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenti...

4 months ago - Business Wire

Another investment bank lifts its price target on the company's stock.

4 months ago - The Motley Fool

ChromaDex (CDXC) delivered earnings and revenue surprises of 9.09% and 0.31%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Shares of ChromaDex (NASDAQ:CDXC) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 9.09% over the past year to ($0.10), which missed the e...

4 months ago - Benzinga

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Earnings--ChromaDex Corp. (NASDAQ:CDXC) today reported fourth quarter and full year 2020 financial results. Fourth Quarter 2020 and Recent Highlights Total net sa...

4 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) announced today its flagship consumer product and industry-leading NAD+ booster Tru Niagen® will be available in 3,000...

4 months ago - Business Wire

On Wednesday, March 10, ChromaDex (NASDAQ:CDXC) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

4 months ago - Benzinga

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #HealthyAging--ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation at the Oppenheimer 31st Annual Healthcare Conference on Wednesd...

4 months ago - Business Wire

ChromaDex (CDXC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

4 months ago - Zacks Investment Research

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced today it has appointed David L. Katz, MD, MPH, FACPM, FACP, FACLM - CEO of Diet ID, Inc, founder and forme...

4 months ago - Business Wire

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Chromadex Corp (NASDAQ: CDXC) shares jumped 111% in the regular and after-hours sessions today. What Happened: The price movement on Thursday was accompanied by intense trading with volumes of 116.67 mi...

4 months ago - Benzinga

Promising Phase III clinical results for Covid-19 treatment have investors falling over themselves to buy into ChromaDex stock. The post CDXC Stock: Why ChromaDex Shares Are Rocketing Higher Today appea...

4 months ago - InvestorPlace

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #COVID19research--ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study “Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COV...

5 months ago - Business Wire

ChromaDex Corp (NASDAQ: CDXC) enters into a securities purchase agreement to sell $25 million in common stock via a private placement led by a new international investor. The company will sell around 3....

5 months ago - Benzinga

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ: CDXC) announced today that it has entered into a securities purchase agreement for the sale of $25.0 million of its commo...

5 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., March 10, 2021 at 4:30 p.m. ET to discuss its financial resul...

5 months ago - Business Wire

ChromaDex was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. The information contained in this article in no way represents investment advice or ...

5 months ago - Benzinga

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study “Combined Metabolic Cofactor Supplementation Reduces Liver Fat in Nonalcohol...

5 months ago - Business Wire

ChromaDex (CDXC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a human clinical trial of Niagen® (nicotinamide riboside, or NR) investigating its...

8 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced today the exclusive launch of its TRU NIAGEN® EX Stick Packs with Watsons Hong Kong, available online and ...

8 months ago - Business Wire

Tru Niagen, CDXC's patented product, shows strong promise in billion dollar markets. Market underestimates monopoly length by ~3x.

8 months ago - Seeking Alpha

ChromaDex's (CDXC) CEO Rob Fried on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

ChromaDex (CDXC) delivered earnings and revenue surprises of 36.36% and -0.81%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (Nasdaq:CDXC) today reported third quarter financial results. 2020 Third Quarter and Recent Highlights Total net sales of $14.2 mi...

8 months ago - Business Wire

On Wednesday, November 04, ChromaDex (NASDAQ: CDXC) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

8 months ago - Benzinga

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., November 4, 2020 at 4:30 p.m. ET to discuss its financial res...

8 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study published in The European Molecular Biology Organization Journal looking at the effect...

9 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced its flagship ingredient, Tru Niagen®, is now available in Nestlé Health Science’s new Celltrient™ Ce...

9 months ago - Business Wire

ChromaDex: Blazing Ahead Of Ponce De Leon

9 months ago - Seeking Alpha

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study from Nature Immunology that found nicotinamide riboside (NR) helped energize tumor inf...

9 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced that results from the study “Combined metabolic cofactor supplementation accelerates recovery in mil...

9 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced new preclinical research published in Investigative Ophthalmology & Visual Science finding Niagen® (...

10 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presen...

10 months ago - Business Wire

About CDXC

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of... [Read more...]

Industry
Biotechnology
CEO
Robert Fried
Employees
110
Stock Exchange
NASDAQ
Ticker Symbol
CDXC
Full Company Profile

Financial Performance

In 2020, ChromaDex's revenue was $59.26 million, an increase of 28.01% compared to the previous year's $46.29 million. Losses were -$19.93 million, -38.02% less than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for ChromaDex stock is "Strong Buy." The 12-month stock price forecast is 15.00, which is an increase of 59.24% from the latest price.

Price Target
$15.00
(59.24% upside)
Analyst Consensus: Strong Buy